Current and future therapy options for systemic mastocytosis
Several newly approved and experimental treatments have shown promise in the management of systemic mastocytosis.
Several newly approved and experimental treatments have shown promise in the management of systemic mastocytosis.
Indolent SM may be diagnosed despite the absence of classic symptoms associated with this disorder.
Different KIT mutations in patients with systemic mastocytosis (SM) appear to correlate with certain findings under the microscope.
Vitamin supplements may help relieve chronic itch in people with conditions like systemic mastocytosis, especially when applied topically.
The clinical manifestations of SM vary greatly from patient to patient, with some presenting back pain as an isolated symptom.
A patient with systemic mastocytosis suffered a life-threatening immune reaction after receiving an mRNA-1273 COVID-19 booster.
A patient who was diagnosed with mast cell leukemia, a rare form of SM, experienced symptom relief with methylprednisolone treatment.
A genetic trait that increases risk of anaphylaxis is higher in people with SM. Identifying the trait early could mean better treatment.
A rare case of systemic mastocytosis (SM) manifesting as generalized seizures was recently described in a case report.
A 9-year-old girl underwent a stem cell transplant after being diagnosed with SM following treatment for a germ cell tumor.